QIAGEN acquires remaining stake in NeuMoDx Molecular for $248m
QIAGEN initially acquired a 19.9% stake in NeuMoDx, along with the right to acquire the remaining stake at…
Merck agrees to acquire $1bn equity stake in Seattle Genetics
15 Sep 20Merck will make an upfront payment of $600m along with a $1bn equity investment by acquiring five million…
Gilead Sciences to buy Immunomedics in $21bn deal
14 Sep 20The deal will benefit Gilead with Trodelvy (sacituzumab govitecan-hziy), an advanced Trop-2 directed antibody-drug conjugate, developed by Immunomedics
Takeda to sell European non-core assets to Cheplapharm in $562m deal
09 Sep 20Takeda is expected to receive around $562m in an upfront payment, subject to customary legal and regulatory closing…
Grifols to acquire remaining stake in Alkahest for $146m
08 Sep 20Alkahest is a wholly-owned subsidiary within the Grifols innovation office (GIANT) and is focused on proteins with a…
Nestlé to acquire Aimmune Therapeutics in $2.6bn deal
01 Sep 20Aimmune’s FDA approved Palforzia therapy is expected to expand Nestlé Health Science’s portfolio to reduce the severity of…
Bristol Myers to acquire Forbius for its TGF-beta inhibitor pipeline
25 Aug 20Forbius develops a portfolio of selective potent inhibitors of TGF-beta 1 & 3, which mediate immunosuppression and fibrosis
Takeda to divest consumer health care business to Blackstone for $2.3bn
25 Aug 20The sale of consumer health care business will further strengthen Takeda’s focus on five key business areas, and…
J&J agrees to acquire Momenta Pharmaceuticals for $6.5bn
20 Aug 20The acquisition will enable J&J’s pharmaceutical business Janssen to expand its operations in immune-mediated diseases and autoantibody-driven diseases
Sanofi to acquire Principia Biopharma in $3.68bn deal
18 Aug 20Principia Biopharma is a late-stage biopharmaceutical company that develops transformative therapies for immune-mediated diseases